Trial Profile
A 12-month, Exploratory Open-label Study of Eylea (Aflibercept) in Subjects With Retinal Pigment Epithelial Detachment Secondary to Neovascular Age-related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2020
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Retinal detachment; Wet age-related macular degeneration
- Focus Therapeutic Use
- 15 Feb 2017 Status changed from not yet recruiting to completed.
- 01 Jul 2014 New trial record